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Abstract 
Numerous studies demonstrate a relationship between insulin and Alzheimer’s disease; however, 
little research exists on insulin’s association to Parkinson’s disease (PD) and Parkinson’s disease 
dementia (PDD). The current study examined the connection between insulin and cognitive 
functioning in PD, PDD, and age-matched controls. A total of 22 older adult participants with 
PD completed the present study: 12 participants with PD (mean age = 67.50; 41.67% men; mean 
Mini Mental State Exam (MMSE) = 28.67) and 10 participants with PDD (mean age = 75.10; 
90.00% men; mean MMSE = 22.90). Twenty-two non-demented older adults (mean age = 71.77; 
63.64% men; mean MMSE = 29.23) from the University of Kansas Brain Aging Project served 
as the control group. Participants completed a neuropsychological assessment battery designed to 
represent cognitive domains of interest for individuals with PD and PDD as well as a two-hour 
glucose tolerance test. Total area under the curve (AUC) for blood insulin served as overall 
indices for insulin levels. PDD participants had lower absolute insulin values compared to PD 
participants and lower insulin levels were associated with decreased motor performance based on 
the Unified Parkinson’s Disease Rating Scale (UPDRS) motor score. Contrary to predictions, 
higher insulin levels predicted poorer executive functioning performance for both PD and PDD 
participants. More research is needed to establish specific mechanisms to explain the relationship 
between higher insulin levels and reduced executive functioning performance. Additional 
research would also provide further evidence for insulin’s role in cognitive changes for older 
adults with PD, PDD, and other neurodegenerative diseases. 
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The Neuropsychological Impact of Insulin Levels: 
Roles of Insulin in Parkinson’s Disease and Cognitive Decline 
 
Glucose is a monosaccharide sugar within blood that serves as the brain’s major energy 
source. Insulin is a protein hormone that metabolizes carbohydrates, proteins, and lipids. Insulin 
regulates blood sugar levels by assisting in the uptake of glucose into bodily tissues (White, 
2003). Glucose and insulin have a direct relationship in healthy adults. Before eating, both 
insulin and glucose levels are low. After consuming a meal, blood glucose levels rise and initiate 
insulin release from the pancreas. Even a modest increase in bloodstream glucose quickly results 
in a noticeable increase in insulin secretion (Norman, 2009; White, 2003). When this balance is 
disturbed, diseases like insulin resistance occur because muscle, fat, and liver cells can no longer 
properly respond to insulin. Insulin resistance can lead to obesity, diabetes mellitus (Steinberger 
& Daniels, 2003), and cognitive decline (Arvanitakis, Wilson, & Bennett, 2006; Craft & Watson, 
2004; Sandyk, 1993).  
Insulin receptors play a major role in the central nervous system (CNS). These 
extracellular receptors act as indirect activation pathways to control intracellular activity. The 
indirect activation pathway and signal transduction within a cell begins when insulin molecules 
bind to extracellular subunits (White, 2003). Binding activates the intracellular subunit tyrosine 
kinase and initiates protein phosphorylation of signaling scaffold proteins IRS-1 or IRS-2. 
Following phosphorylation, IRS-1 or IRS-2 recruits and phosphorylates PI 3-kinase. PI 3-kinase 
then activates Akt kinase that continues the signaling pathway by phosphorylating several 
additional substrates involved in cell survival, growth, and glycogen synthesis (White, 2003). 
Insulin signaling also influences GABA, NMDA, and AMPA neurotransmitter receptors. These 
receptors contribute to learning and memory, neuronal circuitry specialization, information 
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storage (van der Heide, Kamal, Artola, Gispen, & Ramakers, 2005), and synaptic plasticity 
(Huang, Lee, & Hsu, 2004). 
Hormonal reserves in the body decline as age increases. Reduction in insulin hormone 
and damage to glucoregulatory mechanisms trigger impaired glucose tolerance, insulin 
resistance, and diabetes mellitus, which are all common in older adults (Gasparini, Netzer, 
Greengard, & Xu, 2002; Sandyk, 1993). Inadequately regulated insulin in diabetes mellitus leads 
to poorer cognitive functioning and more rapid cognitive decline over time (Arvanitakis et al., 
2006; Gregg et al., 2000; Messier & Teutenberg, 2005). Risk factors for diabetes mellitus and 
Alzheimer’s disease (AD), the most common form of dementia (Arvanitakis, Wilson, Bienias, 
Evans, & Bennett, 2004), greatly overlap. Shared risk factors include age, family history, high 
blood pressure, high cholesterol, and insulin resistance (Ott et al., 1999). For this reason, it is not 
surprising that research suggests a close relationship between AD and insulin signaling (Burns et 
al., 2007; Craft & Watson, 2004; Gasparini et al., 2002).  
AD and Parkinson’s disease (PD) have similar biological mechanisms (Weintraub et al., 
2011), so it is likely that insulin signaling impacts and exacerbates PD (Fantini & Yahi, 2010; 
Rodolfo, Ciccosanti, Giacomo, Piacentini, & Fimia, 2010). Numerous studies illustrate the 
relationship between insulin and AD; however, there is a paucity of data on insulin’s association 
to PD and Parkinson’s disease dementia (PDD). Furthermore, to our knowledge, little research 
has investigated insulin metabolism in PDD.  
This study examined insulin’s relationship with cognitive functioning in PD, PDD, and 
age-matched controls. We hypothesized that (1) the PDD group would have lower absolute 
insulin, as defined by insulin area under the curve (AUC) for a two-hour glucose tolerance test, 
compared to PD and control groups; (2) Lower insulin levels would significantly correlate with 
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decreased motor performance, as defined by the Unified Parkinson’s Disease Rating Scale 
(UPDRS) motor score; (3) Lower insulin levels would predict poorer performance on executive 
functioning, memory, visuospatial, and language tasks. This research adds to the literature about 
the impact of insulin on cognitive performance in PD and PDD. Future use of this knowledge 
could streamline diagnosis of PD and PDD, improve treatment, and help to better understand the 
aging process.  
Parkinson’s disease 
Parkinson’s disease (PD) is the second most common degenerative neurological disorder 
and can affect 0.6% of the population ages 65-69 and 2.6% of those ages 85-89 (Irvine, El-
Agnaf, Shankar, & Walsh, 2008). In America, prevalence rates are as high as 1.5 million 
individuals with 500,000 new diagnoses each year (Weintraub, 2004). Approximately 3% of the 
population above the age of 65 (Moghal, Rajput, D’Arcy, & Rajput, 1994) and one in ten people 
over the age of 80 have PD (Bennett et al., 1996).  
Age is the most consistent predictor of PD (Morens et al., 1996); however, the disease is 
not confined to older adults. Five to ten percent of individuals experience parkinsonian 
symptoms before age 40. Development of PD in midlife is defined as “young-onset Parkinson’s 
disease” (Moghal et al., 1994). The disease impacts all ethnic groups, but a greater frequency of 
Caucasians are diagnosed compared to Asians and African Americans. Males are diagnosed with 
PD at a greater frequency than females (Zhang & Roman, 1993).   
PD is often associated with difficulties in movement. Classic symptoms include 
bradykinesia, extreme slowness in movement, or akinesia, absence of voluntary movement. 
Tremors, rigidity, and postural abnormalities also characterize the illness (Lang & Lozano, 1998; 
Slaughter, Slaughter, Nichols, Holmes, & Martens, 2001). Parkinsonian symptoms are also 
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associated with other causes including other neurodegenerative diseases, Wilson’s disease, and 
antipsychotic medications such as haldol and risperdal (de Rijk et al., 1997). However, resting 
tremor, asymmetry of symptoms, and a positive response to the medication levodopa 
distinguishes PD from parkinsonian symptoms resulting from other factors (Lang & Lozano, 
1998). Slight tremor in one hand and increased stiffness in the limbs are often attributed to the 
aging process and result in the underdiagnosis or misdiagnosis of many individuals. Parkinsonian 
symptoms are chronic and progressive, but the manifestation and progression of symptoms vary 
greatly among patients. Typically individuals do not become incapacitated from symptoms until 
10-20 years after the onset of symptoms. In advanced stages, those with PD require assistance 
with feeding, washing, and other functions of daily living (Caballol, Marti, & Tolosa, 2007). PD 
symptoms gradually become more serious but are not considered fatal. Complications from the 
disease such as choking and falling more often lead to death. The average life expectancy after 
diagnosis is nine years (Lang & Lozano, 1998).  
Non-motor symptoms frequently develop in PD. These include hallucinations, anxiety, 
complex behavioral disorders, sensory dysfunction with hyposmia or pain, disturbances of sleep-
wake cycle regulation, and cognitive dysfunction (Barnes & Boubert, 2008; Poewe, 2008; van 
Rooden, Visser, Verbaan, Marinus, & van Hilten, 2009; Weintraub, Moberg, Duda, Katz, & 
Stern, 2004).  
Cognitive decline in Parkinson’s disease 
 Meta-analytic results indicate that non-demented PD patients show a relatively small 
decline in cognitive functioning during a 2.5-year follow-up period (Muslimovic, Schmand, 
Speelman, & DeHaan, 2007). Prevalence rates of individuals experiencing cognitive deficits 
without dementia are uncertain. However, research indicates that 36% of individuals with a 
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recent PD diagnosis present some form of cognitive impairment (Foltynie, Brayne, Robbins, & 
Barker, 2004). In addition, researchers found that 55% of a non-demented PD sample had mild 
cognitive impairment (Jarvin, Aarsland, Larsen, & Hugdahl, 2003).   
Executive dysfunctions are typically the first cognitive deficits to occur in PD 
(McKinlay, Grace, Dalrymple-Alford, & Roger, 2010; Robottom & Weiner, 2009; Williams-
Gray et al., 2009), and these impairments are the most sensitive neuropsychological predictors of 
progression of cognitive impairment in PD (Stepkina, Zakharov, & Yakhno, 2010). Executive 
functioning is defined as various higher-order capacities that involve the organization and 
prioritization of thoughts and tasks, inhibition of activity and emotions, decision making, 
planning, time management, shifting mental effort, short-term memory, and working memory 
(Barnes & Boubert, 2008; Campos-Sousa, Campos-Sousa, Ataide, de Brito Soares, & Almeida, 
2010; Fernandez, Crucian, Okun, Price, & Bowers, 2005). Executive functioning is involved in 
the control and expansion of both cognitive and behavioral responses to environmental situations 
(Caballol et al., 2007; Williams-Gray, Foltynie, Brayne, Robbins, & Barker, 2007). In PD, 
executive functioning impairments are noted through poor performance on generating mental 
sets, set shifting, planning, attention, and determining sequence of events (Robottom & Weiner, 
2009). In some individuals, executive functioning deficits are subtle and difficult to detect with 
screening measures (Robottom & Weiner, 2009).  
Executive dysfunctions in PD can elicit abnormalities in memorization (Baran, Tekcan, 
Gurvit, & Boduroglu, 2009). Difficulties in memorization can lead to disruption of sequencing 
and encoding new memories (Bohlhalter, Abela, Weniger, & Weder, 2009; Robottom & Weiner, 
2009). Research shows non-demented PD patients experience deficits on tasks of immediate and 
delayed recall (Baran et al., 2009) and reduced performance on word list learning (Anderson, 
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2004; Caballol et al., 2007; Merims & Freedman, 2008; Williams-Gray et al., 2007). However, 
significant memory impairments may occur only when tasks require greater attention, learning 
strategies, and planning (Baran et al., 2009). Typically the ability to learn new information and 
recognition remains in tact (Bohlhalter et al., 2009). These data suggest that deficits involving 
the coding and retrieval of information are impacted more so than the storage of information 
(Caballol et al., 2007).   
While executive dysfunctions are the first cognitive impairments to occur in PD, 
visuospatial deficits are reported with greater frequency (Robottom & Weiner, 2009). In 
addition, research demonstrates that those PD patients with severe visuospatial deficits have a 
quicker progression of cognitive impairments compared to those with less visuospatial deficits 
(Stepkina et al., 2010). Visuospatial function is the ability to manipulate and synthesize graphic, 
geographic, or non-verbal information (Fernandez et al., 2005). In PD, visuospatial abnormalities 
present during visual orientation, visual attention, spatial planning, and spatial memory tasks 
(Robottom & Weiner, 2009). Along with memory impairments, visuospatial deficits are thought 
to relate to executive functioning and disruption of information integration (Robottom & Weiner, 
2009). However, some research suggests visuospatial abilities are independent of executive 
function. In one study, problem solving deficits were apparent only in tasks with high 
visuospatial content (e.g., Matrix Reasoning; McKinlay et al., 2010).  
Language impairments also occur in PD. Deficits present through speech hesitation and 
perseveration intrusions during word fluency tasks. Individuals can experience these difficulties 
in category, letter (Robottom & Weiner, 2009), and semantic fluency (Baran et al., 2009; 
Caballol et al., 2007). Research also has shown that PD patients have trouble with verb naming 
(Caballol et al., 2007). Language deficits likely result from an inability to plan and implement 
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motor aspects of language, capacities that are connected to executive functioning, thereby 
strengthening the argument that executive functioning deficits are primary in PD. In general, 
language is preserved and there is little evidence of aphasia in PD. (Robottom & Weiner, 2009). 
Parkinson’s disease dementia 
Prevalence rates of Parkinson’s disease dementia (PDD) range from 20-80% (Anderson, 
2004; Galvin, 2006; Lang & Lozano, 1998; Merims & Freedman, 2008; Williams-Gray et al., 
2007). Researchers found that within five years following a PD diagnosis, 17% of a United 
Kingdom study cohort had dementia (Williams-Gray et al., 2009). Another study surveying the 
population of Norway found that 65% of a surviving cohort with PD had dementia (Mayeux et 
al., 1990). If higher prevalence rates are accurate, PDD is the second most common type of 
dementia (Fernandez et al., 2005). Patients with PD are diagnosed with dementia at a frequency 
of 2 to 6.6 times greater than that of healthy older adults (Caballol et al., 2007; Mayeux et al., 
1990; Robottom & Weiner, 2009). Risk factors for developing PDD include advanced age at the 
onset of motor symptoms, severe motor symptoms, male sex, depression, smoking, and early 
development of l-dopa related confusion or psychosis (Anderson, 2004; Galvin, 2006; Merims & 
Freedman, 2008; Muslimovic et al., 2007; Williams-Gray et al., 2007).  
One study found that out of 100 PD patients, 31 patients had well-documented dementia. 
Nine PD patients met criteria for AD (29%), three patients met criteria for diffuse Lewy body 
disease (10%), and two PD patients had possible vascular dementia (6%). The researchers 
reported that the remaining 17 PD patients with dementia (55%) had no definite pathological 
explanation for the cognitive decline other than PD (Hughes, Daniel, Blankson, & Lees, 1993). 
These results highlight how symptom similarities among PD, AD, and dementia with Lewy 
bodies cause difficulty in exact diagnoses. Also, the Diagnostic and Statistical Manual of Mental 
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Disorders Fourth Edition (DSM-IV) defines PDD as “cognitive and motoric slowing, executive 
dysfunction, and impairment in memory retrieval” (American Psychiatric Association, 2000). 
The requirement of memory retrieval difficulties is one result of using the DSM-IV definition. 
While this is a common impairment, it may not be a prominent characteristic of PDD. This 
generalized definition of dementia could be one factor contributing to the wide prevalence ranges 
and controversial nature of PDD.  
Cognitive decline in PDD is insidious with a slow progression. PDD commonly begins 
with slowing thoughts. However, researchers concluded that slowing thoughts were not a simple 
byproduct of motor symptoms (Berardelli et al., 2001, as cited in Gavin, 2006). PDD later 
progresses to increased difficulties in memory, visuospatial skills, language, abstract thinking, 
behavioral regulation, and motivation (Anderson, 2004; Caballol et al., 2007; Muslimovic et al., 
2007). PDD patients have increasing trouble with housework or finances due to the extra time 
needed to complete tasks. Reduced participation in social gatherings as well as avoidance of 
decision-making or initiation of activities is common. PDD patients experience visual and 
auditory hallucinations, delusions, and depression more frequently compared to non-demented 
PD patients (Caballol et al., 2007; Galvin, 2006).  
Similar to PD, PDD patients demonstrate greater impairment on executive functioning 
tasks compared to individuals with AD (Robottom & Weiner, 2009). Individuals with PDD also 
demonstrate reduced performance on attentional tasks and in motor reaction time (Galvin, 2006). 
Some researchers report that PDD and AD have similar attentional impairments (Robottom & 
Weiner, 2009); however, attention may fluctuate more in PDD. Reaction time and vigilance 
likely contribute to attentional deficits. In addition, PDD causes difficulties in set switching, 
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concept formation, problem solving, and speed of information processing (Robottom & Weiner, 
2009).   
Researchers found that 67% of PDD patients experience memory deficits (Emre, 2003). 
Memory deficits result from failing to retrieve information rather than trouble encoding 
information. Unlike non-demented PD patients, PDD patients show greater recognition deficits 
(Bohlhalter et al., 2009). Cueing may help reduce impairments in semantic and episodic memory 
(Robottom & Weiner, 2009). Compared to semantic and episodic memory deficits, a lack of 
evidence exists for an association between PDD and verbal memory deficits (Stepkina et al., 
2010).  
Visuospatial deficits also present in PDD. These impairments are subtle at first but often 
appear before an official dementia diagnosis is given. Visuospatial deficits in PDD are more 
severe compared to similar dementia severity in AD (Robottom & Weiner, 2009).  
In PDD, the extent of language impairments varies, but aphasia typically does not 
develop. Verbal fluency deficits often emerge before an official dementia diagnosis is given. 
Reduced speech, shorter phrase length, trouble naming objects, and dysarthria also occur in PDD 
(Robottom & Weiner, 2009). Compared to AD, those with PDD have greater motor speech 
difficulties (Robottom & Weiner, 2009). At a six-month follow-up, researchers found that 
deterioration of cognitive functions was associated with trouble actively reproducing verbal 
material; however, prompting enhanced reproduction of material (Stepkina et al., 2010). In 
addition, PDD patients can experience comprehension difficulties with metaphors or ambiguous 
language content (Lewis, Lapointe, Murdoch, & Chenery, 1998). 
Neuroanatomy of Parkinson’s disease 
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Numerous brain structures contribute to the symptomatology of PD and PDD. Structures 
of the basal ganglia play a key role in PD by regulating movement and motor control (Higgins & 
George, 2007). The basal ganglia consist of the putamen, globus pallidus, and caudate nucleus 
that lay under the anterior portion of the forebrain cortex. The basal ganglia share connections 
with other structures including the cerebral cortex. One pathway begins as regions of the cortex 
send neural signals to the caudate nucleus. The neural signals pass through the caudate nucleus 
and continue through the putamen, globus pallidus, and thalamus until they reach frontal regions 
of the cortex (DeLong & Wichmann, 2009; Higgins & George, 2007; Pliszka, 2004). Disruptions 
to the basal ganglia including deterioration in the connections to the substantia nigra pars 
compacta cause difficulties in initiating or executing movements and impact the speed and 
amplitude of movements. In addition, postural changes and increased or decreased muscle tone 
result from damage to the basal ganglia (DeLong & Wichmann, 2009).   
The nigrostriatal dopamine pathway is another crucial component to the neuroanatomy of 
PD and PDD. This important midbrain pathway comprises the substantia nigra’s connections to 
the basal ganglia. Darkly pigmented neurons of the substantia nigra regulate initiation and 
orientation of critical movement (Uversky & Eliezer, 2009). The substantia nigra consists of two 
parts, pars reticulata and pars compacta, with contrasting functions (Pliszka, 2004). The pars 
reticulata continuously fires the inhibitory neurotransmitter GABA. As the pars reticulata 
releases GABA, eye, trunk, and walking movements are stopped. Initiation of these movements 
requires removal of GABA’s inhibitory influence. Dopaminergic neurons in the pars compacta 
withdraw the inhibitory influence and allow initiation of new movement (Pliszka, 2004).    
In PD, connections between the substantia nigra pars compacta and the basal ganglia 
deteriorate and result in dopaminergic cells loss (Pliszka, 2004; Uversky & Eliezer, 2009). Cell 
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loss of the nearly 400,000 dopaminergic cells of the substantia nigra is estimated to occur at a 
rate of approximately 2,400 cells per year. This rate of cell loss is capable of producing PD in an 
otherwise healthy 120-year-old individual. However, PD accelerates the typical rate of cell death 
and causes idiopathic onset around age 70 (Uversky & Eliezer, 2009). Neuronal death in the 
nigrostriatal dopamine pathway initiates classic hypokinetic symptoms of PD including tremors, 
bradykinesia, and difficulty maintaining balance (Uversky & Eliezer, 2009).   
Cortical and subcortical structures contribute to dementia in PD. One theory proposes 
that disruption to the connections between the basal ganglia and frontal cortex leads to cognitive 
impairments associated with PDD (Stepkina et al., 2010). Research suggests that disturbances in 
the frontal lobe result in executive dysfunction (Caballol et al., 2007). Other theories focus on 
dopaminergic cell loss. Studies suggest that greater substantia nigra cell loss along with 
augmented involvement of caudate nucleus projections generate enhanced cognitive dysfunction 
(Caballol et al., 2007; Gibb & Lees, 1991). Dopamine impacts higher cognitive functions. 
Consequently, reduced dopamine receptors and decreased dopamine transporter density 
diminishes executive function and working memory performance (Seidler et al., 2009).  
Molecular basis of Parkinson’s disease 
Along with brain structures, components at the molecular level play a role in PD and 
PDD. Dopamine’s important role in PD requires additional discussion at the neurotransmitter 
level. Dopamine is a monoamine neurotransmitter formed by the decarboxylation of dopa. Dopa 
is an amino acid produced in the liver during melanin and epinephrine synthesis. Dopamine has 
five different receptors, D1 through D5, and is essential for normal CNS functioning (Pliszka, 
2004). Voluntary movement is controlled by dopamine and a lack of the neurotransmitter causes 
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difficulty in the execution of smooth, controlled movements. Dopamine also plays a part in 
controlling motivation, sleep, mood, attention, cognition, and learning (Brooks & Piccini, 2006). 
Dopamine receptors D1 and D2 are reduced in the aging brain, with a 5-10% loss each 
decade (Seidler et al., 2009). Over 70% of total dopaminergic neurons are lost by the time 
Parkinsonian symptoms become evident (Irvine et al., 2008; Uversky & Eliezer, 2009). Lab 
analyses on brains of deceased PD patients revealed that dopamine amounts were diminished by 
over 90% and to undetectable levels in some cases (Fearnley & Lees, 1991). Even though PD is 
characterized by dopaminergic cell loss, not all dopaminergic projections are impacted equally. 
In general, loss is greatest in the ventrolateral tier of the substantia nigra with decreasing loss in 
the medial ventral tier and dorsal tier. The substantia nigra pars compacta loses 0.5-0.7% of 
dopaminergic cells annually (Seidler et al., 2009). This dopamine neurotransmitter degradation 
pattern is specific to PD and can defer the loss pattern seen in typical aging (Fearnley & Lees, 
1991). Research lacks clear answers for why dopaminergic neuron vulnerability leads to PD.  
One neurotransmitter with a role in PD is glutamate. Glutamate is synthesized from 
glucose (Higgins & George, 2007; Pliszka, 2004) and acts as the major excitatory 
neurotransmitter in the CNS, accounting for over half of all excitatory neurons (Reis et al., 2009; 
Riedel, Platt, & Micheau, 2003). Glutamate has three ionotropic receptors: α-amino-3-hydroxy-
5-methyl-4-isoazole propionic acid (AMPA), N-methyl-D-aspartate (NMDA), and 2-carboxy-3-
carboxy-methyl-4-isopropenyl-pyrrolidine (kainate), (Higgins & George, 2007; Reis et al., 
2009).  
AMPA receptors are located throughout the brain and have high concentrations within 
the neocortex, basal ganglia, thalamus, hypothalamus, hippocampus, cerebellum, and spinal cord 
(Riedel et al., 2003). AMPA and NMDA control the majority of excitatory post-synaptic effects 
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at cell synapses. AMPA and kainate receptors provide quick and immediate postsynaptic 
responses to glutamate release (Riedel et al., 2003). Glutamate attaches to AMPA and kainate 
receptors and causes ligand-gated ion channels to open. This opening allows an exchange of 
sodium (Na+) into a cell and subsequent exit of potassium (K+) out of a cell. Na+ and K+ 
exchange leads voltage-gated Na+ channels to open, resulting in an action potential (Pliszka, 
2004).   
NMDA receptor concentrations are uneven with higher concentrations within the 
hippocampus, thalamus, and cortex and lower concentrations within the basal ganglia, 
cerebellum, and spinal cord (Riedel et al., 2003). The complex NMDA channel allows calcium 
(Ca2+) into a cell (Higgins & George, 2007). To allow Ca2+ into a cell, glutamate and glycine, an 
amino acid, must bind to a NMDA receptor site. However, resting neurons have a magnesium 
(Mg2+) ion blocking Ca2+ channels. AMPA and kainate receptors displace the Mg2+ ion through 
depolarization and permit the calcium influx through the ionophore. The resulting calcium influx 
stimulates a series of enzymes to act as second messengers (Higgins & George, 2007). 
Another neurotransmitter involved in PD is synthesized from glutamate, gamma (g)- 
aminobutyric acid (GABA). GABA is highly concentrated in the substantia nigra and the globus 
pallidus portion of the corpus striatum, with slightly lower concentrations in the hypothalamus, 
periaqueductal grey matter, and hippocampus (Reis et al., 2009). Unlike glutamate, GABA is the 
main inhibitory neurotransmitter in the central nervous system (Higgins & George, 2007). 
Inhibition is an important mechanism that requires precise control for optimal functioning. Too 
little inhibition can produce seizures. Too much inhibition results in a generalized depression of 
brain activity and may cause loss of consciousness (Higgins & George, 2007; Pliszka, 2004).   
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GABA interacts with both ionotropic receptors (GABAA) and metabotropic receptors 
(GABAB), (Pliszka, 2004). Activation of GABAA elicits a conformational change and opens ion 
channels to allow an influx of chlorine (Cl-) into the postsynaptic cell. This results in 
hyperpolarization and thus an inhibitory postsynaptic effect (Reis et al., 2009). GABA creates 
mainly inhibitory responses; however, the neurotransmitter can control output of neurons 
responsible for excitatory functions through increased Cl- concentrations and membrane 
depolarization (Matsuyama, Taniguchi, Kadoyama, & Matsumoto, 2008).   
Insulin 
 Insulin is a polypeptide hormone necessary for adequate health that plays a key role in 
the CNS and neurodegenerative diseases like PD (Gasparini et al., 2002). The majority of studies 
focus on insulin located outside the CNS. In the periphery, β-cells within the pancreatic islet 
produce insulin (Norman, 2009). As individuals consume carbohydrates or sugars, the molecules 
are absorbed through intestinal walls and travel into the bloodstream. When pancreatic islets 
detect increased blood sugar, insulin is synthesized and secreted. As insulin circulates in the 
bloodstream, it attaches to insulin receptors located on most cells. Once insulin binds to a cell’s 
surface, other receptors are activated to absorb glucose into the cell (Norman, 2009). Glucose 
and insulin act in concert; modest increases in plasma glucose result in marked increases in 
insulin secretion into the bloodstream. Healthy individuals achieve homeostasis when plasma 
glucose levels are maintained within a narrow range (Norman, 2009; White, 2003).   
 Disrupted glucose and insulin levels cause diseases such as heart disease, high blood 
pressure, high cholesterol, and obesity. Diabetes mellitus is the most common disease resulting 
from a glucose and insulin imbalance (Arvanitakis et al., 2006; White, 2003). Type I diabetes is 
the body’s inability to sense glucose or secrete insulin. An autoimmune-mediated process 
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destroys β-cells in the pancreas and leads to total insulin deficiency. Type II diabetes occurs 
when the body has diminished sensitivity to peripheral insulin at the receptor level. In contrast to 
Type I diabetes, insulin resistance characterizes Type II diabetes. Insulin resistance is the body’s 
inability to respond properly to insulin (White, 2003). Type II diabetes’ prevalence is rapidly 
increasing in the United States due to the increased prevalence of obesity (White, 2003) and 
leading to numerous health care complications and risks including coronary heart disease, 
learning and memory deficits, and PD and PDD (Arvanitakis, Wilson, Bienias, & Bennett, 2007; 
Hu, Jousilahti, Bidel, Antikainen, & Tuomilehto, 2007). Type II diabetes accounts for 
approximately 90% of all diabetic cases, with higher prevalence in older adults (Arvanitakis et 
al., 2006).   
Insulin Signaling Pathway 
To provide increased understanding of insulin’s role in the body and its connection to 
PD, a microscopic analysis is warranted. Insulin receptors are located and expressed in all 
regions of the brain and act as a model for integral membrane proteins (White, 2003). Domains 
on each insulin receptor are extracellular and act as indirect activation pathways to control 
activity of intracellular tyrosine kinase. To control the activity of tyrosine kinase, translation is 
necessary. In genetics, translation is a process where messenger RNA creates a string of amino 
acids on a ribosome to act as a template for protein formation. During translation, two 
corresponding pro-receptors form a dimer, a molecule comprised of two identical and simpler 
molecules, linked by two disulfide bonds. The disulfide bond is cleaved to create a tetramer of 
two αβ dimers (White, 2003). The indirect activation pathway and signal transduction within a 
cell begins when an insulin molecule binds to the extracellular α subunits. This binding activates 
tyrosine kinase, located on the β subunits inside the lipid bilayer membrane. Tyrosine kinase 
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activation leads to recruitment and phosphorylation of signaling scaffold proteins known as 
insulin receptor substrate protein one (IRS-1) or insulin receptor substrate protein two (IRS-2). 
IRS-1 is responsible for activating peripheral insulin and body growth. IRS-2 plays a role in 
regulating body weight, glucose homeostasis, female fertility, and brain growth. The tyrosine 
phosphorylation of IRS-1 or IRS-2 mediates production of most, and potentially all, signals 
through the insulin pathway (White, 2003).      
After IRS-1 or IRS-2 is phosphorylated, it recruits and phosphorylates 
phosphatidylinsitol (PI) 3-kinase, an effector protein. Effector proteins are molecules that bind to 
other proteins and alter their functioning (Philpott, McCarthy, Klippel, & Rubin, 1997). Once PI 
3-kinase is phosphorylated, it activates protein kinase B, also known as Akt kinase. Following 
Akt kinase activation, the insulin signaling pathway continues by phosphorylating several 
additional substrates. Examples of such substrates include BAD that is responsible for cell 
survival, and GSK3β that controls growth and glycogen synthesis (White, 2003).   
Positive insulin consequences in the brain 
Researchers believe that through the insulin signaling pathway, insulin promotes 
neuronal survival. One study showed that Akt kinase plays a role in cerebellar granule neurons 
survival and protects from fibroblast cell death (Philpott et al., 1997). Also, research found that 
inhibition of PI 3-kinase does not cause apoptosis, programmed cell death, if cells are supplied 
with nerve growth factor (Philpott et al., 1997). Furthermore, activated and over-expressed Akt 
kinase is both necessary and sufficient to activate insulin-like growth factor-1 (IGF-1). IGF-1 can 
prevent nitric oxide toxicity apoptosis (Matsuzaki et al., 1999) or hypoxia (Yamaguchi et al., 
2001) within hippocampal cells. 
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In addition to protecting against programmed cell death, the insulin signaling pathway 
acts as a go-between for various mechanisms responsible for learning and memory (Huang et al., 
2004). Recent studies have demonstrated that PI 3-kinase and Akt kinase are involved in long-
term potentiation (LTP) and long-term depression (LTD). Both LTP and LTD are key steps for 
specialization of neuronal circuitry and information storage in the brain (van der Heide et al., 
2005). LTP is a long-lasting strengthening in a post-synaptic neuron’s response resulting from 
repeated stimulation (van der Heide et al., 2005). LTD is a use-dependent decrease in 
effectiveness of post-synaptic neurons (Huang et al., 2004). LTP also accounts for many forms 
of learning and shares features with long-term memory (Lynch, 2004). Nasally administered 
insulin improves memory in humans (Benedict et al., 2007). More specifically, intranasal insulin 
showed both acute and long-lasting positive effects on declarative memory (Reger et al., 2006). 
Also, intracerebroventricular insulin injections were shown to enhance performance on 
avoidance tasks (Park et al., 1995, as cited in Messier & Teutenberg, 2005). Giving insulin or 
insulin analogs may reduce cognitive decline resulting from inflammation and oxidative stress, 
and for this reason may potentially provide clinical benefits for dementia patients (Torres-
Aleman, 2007).  
Furthermore, the insulin signaling pathway may influence GABA, NMDA, and AMPA 
neurotransmitter receptors. Along with the PI 3-kinase and Akt kinase pathway, these receptors 
are associated with synaptic plasticity (Huang et al., 2004; van der Heide et al., 2005). Synaptic 
plasticity is the continual changing of neuronal pathways in the brain in response to experience 
or injury. This process is crucial for learning and memory because as new experiences are 
encountered, certain neuronal pathways are strengthened while others are modified or eliminated 
(van der Heide et al., 2005). Insulin also has a regulatory role in neuronal excitation and control 
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over ion channel activity. Insulin can recruit GABAA receptors to postsynaptic regions and 
augment NMDA synaptic transmission in hippocampal neurons. Overall, insulin along with 
dopamine, GABA, NMDA, and AMPA receptors influence synaptic changes and impact 
learning and memory.  
Neurotransmitters’ role in learning and memory 
In terms of learning and memory processes, activation of D1 receptors in the nucleus 
accumbens regulates attainment and performance of instrumental learning (Hernandez et al., 
2009). Also, research suggests that this dopamine receptor has more motor performance 
involvement early in the learning period, but participation decreases once proficiency is achieved 
(Hernandez et al., 2009). Similar to AMPA and NMDA receptors, D1 receptors are primarily 
involved in encoding task-related information rather than memory consolidation. Furthermore, 
D1 receptors allow attainment of and action to environmental stimuli as well as the ability to 
process actions results (Hernandez et al., 2009).  
NMDA receptors play a primary role in the learning and memory process of encoding, 
but little evidence suggests function in memory consolidation and retrieval (Hernandez, 
Andrezejewski, Sadeghian, Panksepp, & Kelley, 2009; Riedel et al., 2003). Rats born with 
higher hippocampal NMDA receptor levels show a higher learning capacity (Keller, Borghese, 
Carrer, & Ramirez, 1992). Evidence demonstrates that blocking NMDA receptors during 
learning prevents conditioning and results in amnesia. However, NMDA receptor blockage does 
not consistently result in negative consequences. Older adults may benefit from NMDA receptor 
blockage because previously learned information is protected from retroactive interference or 
forgetting (Norris & Foster, 1999). Furthermore, NMDA receptors impact the functions of 
instrumental learning (Hernandez et al., 2009), spatial learning, fear conditioning, olfactory and 
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taste memories, and locomotion activities (Riedel et al., 2003). Evidence that AD patients have 
reduced NMDA and glutamate binding in the hippocampus compared to healthy age-matched 
controls supports NMDA’s role in memory. Synaptic plasticity is thought to be a process that 
allows the brain to store memories. Evidence exists that NMDA receptors play unique roles in 
regulating genes required for long-term maintenance of changes in the strength of synaptic 
connections (Rao & Finkbeiner, 2007) in addition to triggering learning-related plasticity (Zhuo, 
2009).  
 Compared to NMDA receptors, relatively little evidence demonstrates AMPA receptors’ 
function in memory formation (Riedel et al., 2003). A difficulty encountered when attempting to 
block AMPA receptor sites is one reason for the research gap. Blocking AMPA receptor sites 
reduces NMDA receptor activation due to reduced postsynaptic depolarization. When AMPA 
receptors are blocked, neuronal communication and essential learning components are 
terminated (Riedel et al., 2003). Data suggests that AMPA receptor activation is crucial for 
memory consolidation and recall (Jerusalinsky, et al, 1992, as cited in Riedel, et al., 2003), but 
other studies contradict this finding (Hernandez et al., 2009). AMPA receptor activation is 
necessary for spatial learning. If hippocampal AMPA substrate (GluR2) is lacking, the stability 
and accuracy of cell firing and spatial learning is compromised (Yan et al., 2002).  
While a paucity of data exist to support AMPA’s position in the process of learning and 
memory, some evidence shows learning-induced changes to the receptor (Tocco et al., 1991). 
Researchers argue that learning results in new AMPA receptor membrane sites within neuronal 
pathways that increase excitation and increase receptor expression. This was demonstrated 
through increased AMPA receptor binding in the hippocampus within 48 hours of receiving 
classical conditioning (Tocco et al., 1991). AMPA receptors also have a distinct role in 
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controlling short-term changes in synaptic plasticity strength (Rao & Finkbeiner, 2007). Overall, 
it appears AMPA receptors regulate learning-induced neuronal excitation and strengthen event 
encoding and memory enhancement (Riedel et al., 2003).   
Ideal human brain activity relies on a balance of excitation, largely provided by glutamate 
receptors, and inhibition, usually resulting from GABA-mediated neurotransmission (Reis et al., 
2009). Because GABA balances excitation and inhibition, dysfunction of GABA-related 
pathways can lead to psychiatric and neurological disorders including PD (Reis et al., 2009). 
GABA interneurons modify information flow through cortical circuits. If an excess or lack of 
GABA signaling exists, faulty communication and disturbances in the CNS result. These 
alterations or disturbances impact learning, memory, and attentional processes (Reis et al., 2009). 
GABAA receptors in the CNS are important for hippocampal long-term potentiation. 
Evidence demonstrates that both feedforward and feedback hippocampal interneuron circuits 
limit the response to synaptic pathway activation (Matsuyama et al., 2008). Blocking GABAA 
receptors disables these circuits and allows for unchecked neuronal excitation. Researchers 
concluded that GABAA receptor blockage contributes to learning and memory processes by 
improving lost functions in age-related cognitive disorders (Matsuyama et al., 2008). This study 
suggests that treatment of cognitive disorders like PDD could target GABAA receptors. 
Furthermore, GABAB receptors perform an important role in age-related learning impairment 
(Lasarge, Banuelos, Mayse, & Bizon, 2009). Treatment with a GABAB antagonist ameliorated 
discrimination learning deficits that reliably occur in aged rats. Improvement in learning 
discrimination was not demonstrated in young rats without learning deficits. These results 
indicate that GABAB receptors require an optimal level of signaling in order to show maximal 
cognitive performance in young and aged rats (Lasarge et al., 2009). 
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Insulin and Parkinson’s disease  
 Following discussion of how insulin and neurotransmitters are connected to learning and 
memory, it is necessary to provide description of insulin’s relationship to PD. Physiological 
hormone reserves gradually decline as age increases. Impaired hormonal homeostasis, 
particularly glucose homeostasis, is one potential cause of hormonal declines (Sandyk, 1993). 
Damage to glucoregulatory mechanisms are seen through impaired glucose tolerance, insulin 
resistance, and diabetes mellitus, all common disorders in older adults. Approximately 40-83% 
of older adults experience glucose intolerance or diabetes (Gasparini et al., 2002; Sandyk, 1993), 
and over 50% of older adults could have undiagnosed diabetes mellitus. Diagnosing glucose 
intolerance and diabetes mellitus is challenging because glucose tolerance may not become 
significant until the age of 70 (Gasparini et al., 2002; Lipman, Boykin, & Flora, 1974). Glucose 
intolerance is found in various neurological disorders including Huntington’s chorea, tardive 
dyskinesia, and Parkinson’s disease. Furthermore, PD patients have higher rates of glucose 
intolerance compared to healthy older adults (Lipman et al., 1974; Morris, Seim, Bomhoff, 
Geiger, & Stanford, 2011; Sandyk, 1993), and having diabetes is associated with a 36% 
increased risk of developing Parkinson’s disease (Schernhammer, Hansen, Rugbjerg, Wermuth, 
& Ritz, 2011). 
 Despite knowledge of the connections among insulin resistance and Alzheimer’s disease 
(Burns et al., 2007; Gasparini et al., 2002) and stroke (Hu et al., 2007), there is a relative paucity 
of research establishing the relationship between PD, insulin resistance, and diabetes mellitus. 
One study demonstrated that diabetes mellitus was associated with parkinsonian symptoms 
including postural reflex impairments and gait disturbances (Arvanitakis et al., 2007). Diabetic 
older adults scored 0.20 points higher on a measure of global parkinsonian signs compared to 
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non-diabetic older adults. This is equivalent to increasing the impact of parkinsonian symptoms 
by three years. Conversely, tremor, rigidity, and bradykinesia symptoms lacked connections to 
diabetes mellitus (Arvanitakis et al., 2007). A national survey of older adults found elevated 
diabetes mellitus prevalence rates in older adults with PD compared to healthy older adults 
(Pressley et al., 2003). In addition, Type II diabetes strongly correlates with an increased risk of 
PD. Therefore, researchers propose that Type II diabetes mellitus act as a risk factor for the 
development of PD (Hu et al., 2007; Sandyk, 1993).  
Insulin’s relationship to cognitive decline and dementia 
 Both Type I and Type II diabetes mellitus are associated with deficits to the CNS and 
impairments in learning and memory. Most studies report that diabetes mellitus negatively 
impacts cognition and leads to a more rapid decline in cognitive functioning (Arvanitakis et al., 
2006; Gregg et al., 2000; Messier & Teutenberg, 2005). While the majority of studies have 
focused on the connections among diabetes mellitus, cognitive decline, and AD (Arvanitakis et 
al., 2006; Leibson et al., 1997), as previously stated a lack of research investigating the 
connection among diabetes mellitus, PD, and PDD exist. The higher dementia rates observed in 
those with both PD and diabetes mellitus highlight the significance of this research area (Sandyk, 
1993). 
Diabetes mellitus influences some cognitive abilities over others. Diabetes mellitus 
related impairments typically involve verbal memory and complex information processing 
(Awad, Gagnon, & Messier, 2004; Fontbonne, Berr, Ducimetiere, & Alperovitch, 2001; 
Gasparini et al., 2002). One study reported poorer performance on serial learning tasks in older 
adults with diabetes mellitus compared to non-diabetic older adults. Ending trials requiring 
storage and information retrieval presented the greatest difficulty. In addition, diabetic older 
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adults scored lower on the Benton Visual Retention Test (Mooradian, Perryman, Fitten, 
Kavonian, & Morley, 1988). Another study found that individuals with diabetes mellitus scored 
15-20% lower on memory and attentional tasks compared to individuals without diabetes 
mellitus (Arvanitakis et al., 2006). Diabetic women reported increased memory problems 
compared to non-diabetic women. Also, diabetic women showed poorer baseline performances 
on Digit Symbol, Trails B, and m-MMSE measures (Gregg et al., 2000). One longitudinal study 
demonstrated a 40% perceptual speed reduction in individuals with diabetes mellitus compared 
to those without diabetes mellitus. However, no executive dysfunctions or semantic memory 
declines were presented (Arvanitakis et al., 2004). Furthermore, another longitudinal study 
showed that individuals with Type II diabetes mellitus had reduced facial recognition, processing 
speed, and motor function scores (Fontbonne et al., 2001).  
Diabetes mellitus might act as a risk factor for dementia (Fontbonne et al., 2001; 
Gasparini et al., 2002; Leibson et al., 1997) and could increase dementia risk by approximately 
two-to-threefold (Arvanitakis et al., 2006; Ott et al., 1999). Diabetic individuals using insulin 
treatments had significantly higher risks for cognitive decline compared to those not using 
insulin treatments. Also, women with diabetes mellitus for 15 or more years had a 1.4 to 3.2-fold 
increase in cognitive impairments at baseline and a 1.6 to 2.1-fold increased risk of cognitive 
decline compared to non-diabetics (Gregg et al., 2000). These data indicate that patients with 
severe diabetes mellitus or longer disease durations are at greater risk for cognitive dysfunctions 
(Gregg et al., 2000; Ott et al., 1999).  
This study examined insulin’s relationship with cognitive functioning in PD, PDD, and 
age-matched controls. We hypothesized that (1) the PDD group would have lower absolute 
insulin, as defined by insulin area under the curve (AUC) for a two-hour glucose tolerance test, 
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compared to PD and control groups; (2) Lower insulin levels would significantly correlate with 
decreased motor performance, as defined by the Unified Parkinson’s Disease Rating Scale 
(UPDRS) motor score; (3) Lower insulin levels would predict poorer performance on executive 
functioning, memory, visuospatial, and language tasks. This research enhances literature on the 
impact of insulin on cognitive performance in PD and PDD.  
Methods 
Participants 
  Eligible participants were ages 55 to 85 with a diagnosis of PD based on the United 
Kingdom Parkinson’s Disease Society brain bank diagnostic criteria. These criteria require 
bradykinesia and at least one of the following: muscular rigidity; four to six Hertz resting tremor; 
or postular rigidity not caused by primary visual, vestibular, cerebellar, or proprioceptive 
dysfunction. Diagnostic criteria for PDD participants stemmed from recommendations from the 
Movement Disorder Society Task Force for level I testing (Dubois et al., 2007). These criteria 
require: a PD diagnosis as described above; PD motor symptoms that developed prior to the 
onset of dementia; decreased global cognitive functioning defined by a score of 25 or below on 
the Mini Mental Status Examination (MMSE); cognitive deficits severe enough to impair daily 
life; impairment in more than one cognitive domain including executive function, memory, 
visuoconstructive ability, and attention.  
The study sample included 22 older adult participants with PD: 12 participants with PD 
and 10 participants with PDD. The University of Kansas Parkinson’s Disease and Movement 
Disorder Center collected basic demographic information, history of onset and symptoms of PD, 
current medications, type of assistive devices used, and living arrangements for all participants. 
The KU Parkinson’s Disease and Movement Disorder Center evaluated individuals using the 
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Unified Parkinson’s Disease Rating Scale (UPDRS), Mini Mental Status Examination (MMSE), 
and additional assessments as part of another study protocol. MMSE scores in addition to the 
criteria described above determined dementia status. The PD group consisted of individuals with 
MMSE scores above 25, and the PDD group consisted of individuals with MMSE scores of 25 or 
below.  
Non-demented older adults from the University of Kansas Brain Aging Project served as 
the control group. Participant recruitment was conducted from the KUMC Brain Aging Project 
using an established patient registry (Burns et al., 2007). These individuals were evaluated with 
neuroimaging and insulin measures including intravenous glucose tolerance testing procedures 
similar to those the PD and PDD groups completed. Dementia status was determined using the 
Clinical Dementia Rating (CDR) scale that assessed cognitive function across multiple domains 
(Morris, 1993). A global CDR score was based on ratings from each domain, with a CDR score 
of 0 indicating no dementia. Control group participants received a neurological evaluation to 
assess for abnormalities in visual fields, cranial nerves, motor strength, sensation, reflexes, 
plantar responses, coordination, praxis, and gait. The control group consisted of 22 participants 
matched on age and gender to PD and PDD participants. 
Neuropsychological Measures 
 The neuropsychological assessment battery examined executive functioning, memory, 
working memory, visuospatial ability, language, and simple motor speed. These widely used 
measures represented the cognitive domains of interest for PD and PDD participants. The current 
battery contained tests recommended by the Clinical Task Force of the Alzheimer Disease 
Centers (Weintraub et al., 2009) as well as several well-known tests sensitive to visuospatial 
deficits occurring in PD. Many measures were gathered from the Wechsler Adult Intelligence 
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Scale III (WAIS-III), Wechsler Adult Intelligence Scale IV (WAIS-IV), and the Wechsler 
Memory Scale - Revised (WMS-R). These measures were selected because they did not 
demonstrate floor or ceiling effects and showed sensitivity to change over two years in a trial of 
mild cognitive impairment in AD. 
 Mini Mental State Examination (MMSE). This screening scale consisted of 30 items 
that evaluated participants’ orientation to place and time, registration, attention and 
concentration, recall, language, and visual construction. Lower MMSE scores indicated poorer 
performance and greater cognitive impairment (Folstein, Folstein, & McHugh, 1975).  
Logical Memory I and II. Logical Memory I examined memory and assessed recall of a 
short story. Logical Memory II investigated delayed recall of episodic memory (Groth-Marnat, 
2003). Participants were read a short story and immediately asked to retell the story from 
memory. After a period of at least 20 minutes, but no more than 30 minutes from the initial 
reading, participants were asked to recall as much of the story as they could remember. Total 
scores for both immediate and delayed measures were calculated based on the total number of 
accurately recalled story segments.     
Digit Span (Forwards and Backwards). Digit Span Forward evaluated rote learning and 
memory, attention, and auditory processing. Digit Span Backward examined working memory, 
mental manipulation, and visuospatial imaging. Shifting from one Digit Span task to another 
required cognitive flexibility and mental alertness (Groth-Marnat, 2003; Reynolds, 1997). In 
Digit Span Forward, participants were read a sequence of numbers and asked to recall the 
numbers in the same order as presented. In Digit Span Backward, participants were read other 
number sequences and asked to recall the number sequences in reverse order. Both tasks 
contained 12 items with two trials of the same number span length. Digit Span Forwards and 
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Digit Span Backwards total scores were calculated based on the number of correctly recalled 
sequences.  
Category Fluency. Category Fluency examined semantic memory, executive functioning, 
verbal fluency, and language (Weintraub et al., 2009). In this task, participants were given a 
semantic category (e.g., animals and vegetables) and instructed to provide different examples of 
the category as quickly as possible. Each trial was one minute in duration. Scores were 
calculated based on the total number of correct category examples within the time limit.  
Trail Making Test. Trail Making Test evaluated executive functioning and processing 
speed. Part A required visuomotor and perceptual-scanning skills, while Part B required 
visuomotor and perceptual-scanning skills in addition to cognitive flexibility to complete the task 
within a specified time limit (Weintraub et al., 2009). Part A consisted of 25 circles numbered 1 
through 25 scattered across a sheet of paper. Participants were instructed to connect the circles in 
ascending numerical order by drawing a line as quickly as possible without making mistakes. 
Part B consisted of 25 circles containing either numbers (1 through 13) or letters (A through L). 
Participants were instructed to connect the circles in ascending order alternating between 
numbers and letters (i.e., A to 1; 1 to B; B to 2; 2 to C). Total completion time and the number of 
errors were recorded.  
Digit Symbol. This task investigated cognitive flexibility, attention, concentration, 
motivation, processing speed, psychomotor speed, short-term visual memory, learning ability, 
and visual-motor coordination (Groth-Marnat, 2003). Participants were shown boxes where each 
number was associated with a unique symbol. Participants were instructed to quickly copy the 
symbols associated with each number while going in order across the sheet. Total score was 
based on the number of symbols correctly paired with each number within a specific time limit.  
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Boston Naming Test. This measure examined language and was sensitive to aphasia and 
object recognition deficits (Mack, Freed, Williams, & Henderson, 1992; Weintraub et al., 2009).  
Participants were shown pictures of items in order of recognition frequency, from most frequent 
(e.g., house) to least frequent (e.g., palette) and asked to name each pictured item. Participants 
were administered the Boston Naming short form containing 15 pictured items. 
Block Design. This measure investigated the ability to analyze and synthesize abstract 
visual stimuli. Successful completion involved nonverbal concept formation and reasoning, 
simultaneous processing, visuospatial ability, and learning (Carroll, 1993; Groth-Marnat, 2003). 
Participants were shown pictures and asked to recreate presented designs using red- and white-
sided blocks. Total score was based on the number of correctly assembled designs within a time 
limit. 
Stroop Color-Word Test. The Stroop Color-Word Test evaluated executive functioning, 
cognitive flexibility, ability to suppress a habitual response in favor of an unusual one, and 
selective attention (Fisher, Freed, & Corkin, 1990). This task had three subtests, each with a 
unique stimulus card. In the first subtest, participants were presented a stimulus card and 
instructed to name the colors of each box (e.g., red, green, or blue). In the second subtest, 
participants were presented with a stimulus card and asked to read the names of colors (e.g., red, 
green, or blue) appearing in black ink. In the third subtest, participants were shown a stimulus 
card, the interference card, where color words were printed in non-corresponding color inks (e.g., 
the word “red” printed in blue ink). Participants were instructed to ignore the printed words and 
report only the color of ink for each printed word. Each subtest was 45 seconds. Total scores 
were based on the number of correct responses within the time allowed minus response errors.   
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Free and Cued Selective Reminding Test (SRT). SRT investigated memory, learning, 
self-organized retrieval, encoding, and retention (Grober, Ocepek-Welikson, & Teresi, 2009). 
This task consisted of 16 pictures from unique categories. Participants were shown a set of four 
pictures and instructed to identify and name each picture when its category cue was presented 
(i.e., “What is the Animal?”…“An Elephant”). Once all 16 pictures and category cues were 
presented, participants were instructed to count down from 98 for a total of 20 seconds to prevent 
picture rehearsal. Following the interference, memory of pictures was tested by free recall. If any 
items were not retrieved by free recall, the same category cues for those items were provided to 
test cued recall. If participants were unable to recall cued items, they were immediately reminded 
of that item (selective reminding). There were three trials of free and cued recall, each trail 
preceded by 20 seconds of interference. Total score was calculated based on the number of 
retrieved items during free recall and the number of recalled cued items. 
Letter-Number Sequencing. Letter-Number Sequencing examined working memory, 
sequential processing, mental manipulation, attention, concentration, cognitive flexibility, and 
short-term auditory memory (Groth-Marnat, 2003). Participants were read number and letter 
sequences and asked to recall the numbers in ascending order and the letters in alphabetical 
order. Sequences ranged from two to eight letter and number combinations with three trials for 
each sequence length. Total score was based on the number of correct sequences. 
Visual Puzzles. Visual Puzzles investigated nonverbal reasoning and the ability to 
analyze and synthesize abstract visual stimuli. This test also examined simultaneous processing, 
spatial visualization and manipulation, and the ability to anticipate relationships among parts 
(Carroll, 1993; Groth-Marnat, 2003). Participants were shown a puzzle constructed from three 
shapes and instructed to select three response options that reconstructed the puzzle when 
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combined. Total score was determined based on the number of correct combinations chosen 
within a specified time limit.  
Matrix Reasoning. Matrix Reasoning measured classification and spatial ability, broad 
visual intelligence, simultaneous processing, and knowledge of part-whole relationships (Groth-
Marnat, 2003). Participants were shown an incomplete series or matrix and instructed to select a 
picture response option that completes each series or matrix. Total score was based upon the 
number of correctly selected pictures. 
Geriatric Executive Interview (EXIT). This interview contained a variety of items 
designed to detect deficits in executive functioning including frontal release signs (e.g., grasp 
reflex), motor or cognitive perseveration (e.g., echopraxia), verbal intrusions, imitation behavior, 
loss of spontaneity (e.g., word fluency), and environmental dependence (Juby, Tench, & Baker, 
2002). This 25-item face-to-face interview took approximately 15-20 minutes to administer. 
Total score was determined by participant responses, where correct answers received fewer 
points. Higher total scores indicated poor performance and greater cognitive impairment in 
executive functioning. 
Crossing-Off. Crossing-Off evaluated simple motor speed. This task contained 96 
horizontal lines on one sheet of paper. Participants were instructed to place vertical line marks on 
top of each horizontal line as quickly as possible without making mistakes. Total score was 
based upon the number of correct marks completed within one minute. 
Procedure 
Investigators contacted initially eligible individuals for this study, in addition to collateral 
sources of those with PDD, by phone and provided a brief description of the study. Individuals 
were asked questions regarding medical history to verify any existing exclusion criteria including 
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concurrent diagnosis of AD, Type I, or Type II diabetes mellitus. Investigators mailed additional 
study information including consent forms, directions to each study site, parking passes, and the 
investigators’ contact information to individuals interested in participation. 
All participants were consented by an investigator. Each participant was asked to bring a 
collateral source to the initial visit. Investigators reviewed consent forms describing the study 
background and purpose, procedures, and potential benefits and risks to participants. The 
University of Kansas Medical Center Institutional Review Board (IRB) approved all procedures 
and consent forms. Participant questions and any areas of concern were addressed. After consent 
forms were signed, participants in both groups underwent a neuropsychological assessment as 
described below. Investigators scheduled participants for glucose tolerance testing following the 
initial meeting.  
 Neuropsychological Assessment. This visit took place at the University of Kansas 
Alzheimer’s and Memory Program and lasted approximately 1.5 to 2 hours. Participants 
completed paper and pencil tests of memory and general cognitive functioning administered by 
one trained psychometrician. Cognitive testing was administered one-on-one to both PD and 
PDD participants. Investigators minimized potential distractions to the testing process. 
Participants in the control group were tested previously and not evaluated using Visual Puzzles, 
Matrix Reasoning, EXIT, and Crossing-Off tasks.    
 Glucose Tolerance Testing. This visit took place at the General Clinical Research Center 
at the University of Kansas Medical Center and lasted approximately 2 to 2.5 hours. Methods 
used during this portion of the study were similar to the KU Brain Aging Project (Burns et al., 
2007). Nursing staff performed a 13-sample intravenous glucose tolerance test (IVGTT) at 8:00 
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am after participants completed a 12-hour overnight fast of food and drink. Investigators 
encouraged participants to drink water before this visit but abstain from morning medications. 
Nursing staff placed a small, temporary catheter into a vein in the participant’s desired 
arm that was used for administering glucose and drawing blood samples. An IV glucose bolus of 
0.3 g/kg of body weight (approximately 20 grams) was delivered at Time 0. Nursing staff 
collected 13 blood samples at -5, 1, 3, 5, 10, 15, 20, 30, 40, 50, 60, 90, and 120 minutes after 
administration of the glucose bolus. Blood samples were used to determine glucose and insulin 
levels. A total of approximately 100 cc of blood was sampled from each participant. When the 
IVGTT was complete, participants were able to take personal medications and were provided 
with a light breakfast as well as a meal voucher for lunch at the KU Medical Center cafeteria. 
Blood samples were sent to Denver, Colorado for insulin analysis. The 2006 American Diabetic 
Association criteria was used to classify participants as having impaired fasting glucose (fasting 
glucose > 100 mg/dL) or impaired glucose tolerance (2-hour postload glucose level of 140 to 199 
mg/dL).  
Data Analysis 
 Analyses were conducted using PASW Statistics 18.0. Important covariates of age and 
gender were controlled for on all statistical tests. Covariates are variables that may have an 
influence on the criterion variables; however, the effects are not of interest (Witte & Witte, 
2007).  
Student’s t test was used to make comparisons between the means of the PD, PDD, and 
healthy ND control groups on demographic and clinical information. Pearson correlations were 
used to assess relationships between cognitive measures of executive functioning, visuospatial 
ability, memory, language, attention, learning, and problem solving for the PD and PDD groups. 
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Total area under the curve (AUC) for blood concentration over time for both glucose and 
insulin served as overall indices for glucose and insulin levels. This measurement is commonly 
used in diabetes research to evaluate how insulin secretion is impacted following administration 
of glucose (Allison, Paultre, Maggio, Mezzitis, & Pi-Sunyer, 1995; Walker, 1994; Tai, 1994). 
Rather than investigating the body’s insulin response to glucose at a single time point, the AUC 
value is an integrated assessment that evaluates response over a specific amount of time. A single 
insulin measurement is not an accurate depiction of how insulin levels increase after a glucose 
load. Additionally, examining only the peak level of insulin is an inaccurate evaluation because 
insulin secretion might be rapid at first in response to administered glucose, and then might 
decrease quickly. Therefore, an integrated representation of insulin levels over time using the 
AUC may provide the most accurate assessment of how insulin levels respond to administered 
glucose (Walker, 1994).  
When evaluating insulin, a larger AUC value is ideal. A larger insulin AUC value would 
indicate the body is properly responding to an increased amount of administered glucose (Allison 
et al., 1995; Norman, 2009). In diabetes mellitus, the body cannot produce enough insulin or 
properly use insulin to control for the increased glucose following consumption of food or during 
a glucose tolerance test (Norman, 2009; White, 2003). 
Secondary measures included fasting baseline, 30-minute, 1-hour, and 2-hour post-load 
insulin and glucose levels. This study aimed to examine differences in insulin AUC across the 
three study groups. Differences among group means were evaluated using analysis of variance 
(ANOVA). Correlations between insulin measures and neuropsychological measures as well as 
correlations between insulin measures and motor performance were determined.  
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Linear regression analysis describes how the value of a criterion variable changes when 
any one of the predictor variables is varied (Witte & Witte, 2007). Linear regression was used to 
examine the presence of any group x metabolic variable interactions in predicting overall 
cognitive performance and performance on executive functioning, visuospatial ability, memory, 
language, attention, learning, and problem solving tasks. Analyses were conducted within 
diagnostic groups (ND control, PD, and PDD) separately as opposed to all participants 
combined.  
Because of the relatively small sample sizes due to the rarity of the well characterized PD 
and PDD samples, all tests were conducted using bootstrap confidence interval estimation. 
Participants in this study were older and had Parkinson’s disease or Parkinson’s disease 
dementia. Traditional statistics that uphold certain assumptions such as a normal distribution, 
equal variances among samples, and large sample sizes (Sahiner, Chan, Hadjiiski, 2008) may not 
accurately portray results for means and correlations in neuropsychological test performance, the 
differences between groups on insulin AUC, and the presence of group x metabolic variable 
interactions. Bootstrapping is a method for gaining a true estimation of performance when a 
sample does not follow traditional statistical assumptions.  
In bootstrapped estimation, a subset of sample observations are randomly selected with 
replacement until the number of re-sampling observations equals the number of observations in 
the original sample (Daw et al., 2001). This re-sampling process is repeated a large number of 
times, and test statistics such as mean, standard deviation, and confidence intervals are calculated 
for each repetition. This information is used to more accurately estimate the characteristics of the 
original sample, and can be used to determine bias that may be inherent in the sample (Daw et 
al., 2001).  
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In this study, the bootstrapped values were compared to the t-test, ANOVA, and linear 
regression values calculated directly from the data in order to evaluate the amount of bias present 
in the original statistical procedures (e.g., non-normal distribution, unequal variance, and small 
sample size).  
Results 
 A total of 22 older adult participants with PD completed the present study: 12 participants 
with PD and 10 participants with PDD. The groups differed significantly on all demographic 
variables with the PDD participants being older on average, having lower average MMSE scores 
representing greater cognitive impairment, and higher average UPDRS motor scores representing 
greater motor impairment. 
Twenty-two non-demented (ND) older adults from the University of Kansas Brain Aging 
Project (Burns et al., 2007) served as the control group. Control participants were chosen for the 
present study to match on demographic information including age, gender, and MMSE scores. 
Demographic information for participants in the ND control, PD, and PDD groups are shown in 
Table 1. The ND control participants did not differ from the PD and PDD group participants with 
respect to gender. However, the control group differed significantly with respect to age 
compared to the PD group and differed significantly from the PDD group with respect to MMSE 
scores. The significant difference in MMSE scores between the ND control group and the PDD 
group is expected, as this score is representative of cognitive decline inherent in participants with 
PDD.  
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Table 1 
Demographic information for participants in the ND, PD, and PDD groups 
______________________________________________________________________________	  
    
ND Participants      t (df = 20) PD Participants     t (df = 20) PDD Participants 
       (N = 22)        (N = 12)        (N = 10)    
  M       SD        M       SD   M       SD  
_____________________________________________________________________________________	  
 
Gender (M/F)        14/8                    5/7                        9/1 
 
Age  71.77       6.22        – 2.14* 67.50       4.01        – 3.99** 75.10       4.93         
 
MMSE  29.23       1.69        – 0.92 28.67       1.72           6.04** 22.90       2.73  
          
UPDRS     -          -   - 19.58       7.09        – 4.59** 32.40       5.74              
______________________________________________________________________________ 
*. Significant at the 0.05 level (2-tailed). 
**. Significant at the 0.01 level (2-tailed).  
Note. UPDRS not calculated for the non-demented participants 
 
 
Neuropsychological measures 
 Participants in the ND control, PD, and PDD groups completed a 1.5 to 2 hour 
neuropsychological battery. The battery was consistent across the three groups with the addition 
of Visual Puzzles, Matrix Reasoning, Geriatric Executive Interview (EXIT), and Crossing-Off 
for the PD and PDD groups only. Each participant in the PD group was able to complete all tests; 
however, some individuals in the PDD group were unable to complete tests (e.g., Trails B, Digit 
Symbol, Block Design, Stroop Color-Word, SRT, Visual Puzzles, Matrix Reasoning) due to 
difficulties comprehending instructions. Participants unable to complete tests received a score of 
zero on those tests, with the exception of Trails B where the maximum value of 300 seconds was 
assigned. 
 To assess the relationship among task performance on cognitive measures for the ND, 
PD, and PDD groups, bivariate correlations were computed separately for each group. For the 
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PD group, performance was significantly related on tests evaluating memory, working memory, 
executive functioning, visuospatial ability, language, and processing speed. Simple motor speed 
(Crossing Off) was not significantly related to other neuropsychological measures. Table 2 
shows the intercorrelation matrix for the PD group. For the PDD group, performances were 
significantly related on tests evaluating memory, working memory, executive functioning, 
visuospatial ability, processing speed, and simple motor speed. Language performance (Boston 
Naming Test – Short Form) was not significantly related to other neuropsychological measures 
in this group. The intercorrelation matrix for the PDD group is shown in Table 3. Simple 
independent t tests were used to compare the means for the PD and PDD groups on each 
neuropsychological measure and results are presented in Table 4.  
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Table 2: Correlation matrix for neuropsychological measures in PD group. 
 
 
 
 
	   39	  
Table 3: Correlation matrix for neuropsychological measures in PDD group. 
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Table 4 
Comparison of means of neuropsychological measures for ND, PD, and PDD groups 
______________________________________________________________________________	  
    
  Non-Demented          t           PD Participants         t           PDD Participants 
         (N = 22)    ND vs PD    (N = 12)         PD vs PDD (N = 10) 
      M            SD                             M            SD                              M            SD     
______________________________________________________________________________	  
 
Memory 
Logical Mem I              14.64         4.22       – 1.24        12.75        4.33          4.67**       4.50        3.87          
Logical Mem II              13.82         4.07       – 1.57        11.50        4.19          4.85**       3.60        3.27 
SRT 
 T1-FR    8.95      1.91           .06          9.00   2.09       5.28**      3.70        2.63 
 T1-CR    7.05      1.91        – .18          6.92   2.02    – 1.36          9.20        4.98 
 T2-FR  10.77      2.05        – .65         10.42        1.17       6.21**      4.90        2.60  
 T2-CR    5.23      2.05           .65           5.58        1.17    – 1.24*        8.30        4.32 
 T3-FR  10.50      2.76           .63         11.08        2.28       4.53**      5.50        3.47 
 T3-CR    5.05      2.01        – .17           4.92        2.28    – 2.16*        7.80        3.91 
Working Memory 
Digit Span F                     8.77         2.22        – .45           8.42        2.11        1.92          6.90        1.45 
Digit Span B                    5.77          2.16        – .15          5.67        1.78           1.53          4.40        2.12 
Letter-Number Seq          9.55          3.04        – .31          9.25        1.77           4.76**      4.50        2.88   
Executive Functioning 
Category Flu Ani           20.36          5.15         1.12         22.50       5.68           4.54**    12.20        4.80 
Category Flu Veg          14.45          3.69        – .03         14.42        4.60       4.33**      7.10        2.96 
Trails A                          30.23          9.27        – .75         27.92       7.17        – 4.66**    96.10      45.84 
 Errors A                .05            .21           .89             .17          .58       – 1.89            .80          .92 
Trails B                          83.36        29.34        – .39         79.25      28.60       – 6.22**  240.60      77.77 
 Errors B                .64            .90        – .41             .50         1.00      – 1.46          1.50        1.96 
Stroop (# correct) 
 Color                 72.48          9.72        – .33         71.08      14.81         4.27**     37.90      21.55 
 Word                 94.36        13.03        – .62         91.42      13.73         3.97**     58.80      24.29 
 Interference       37.57          8.25           .38         38.67        7.23         6.83**     13.80        9.84 
EXIT-25                              --              --              --            3.42        1.24      – 5.69**     13.30        5.38 
Visuospatial  
Block Design                 36.24         13.04      – 1.07         31.67       9.09          2.99*       16.90      13.99 
Visual Puzzles      --          --             --           13.08       3.70       3.59*         6.80        4.52 
Matrix Reasoning     --          --             --           13.42       3.87       3.84 **       6.50        4.58 
Language 
Boston Naming              14.52             .68        1.39         14.83         .58           3.38*      13.00         1.63 
Processing Speed 
Digit Symbol                  50.55          8.11    – 25.29**       4.08         .97           3.37*        1.90        1.97                  
Simple Motor Speed 
Crossing-Off                      --                --             --           90.42     11.99          2.83*       61.50      30.46 
_____________________________________________________________________________________ 
*. Independent t test is significant at the 0.05 level (2-tailed). 
**. Independent t test is significant at the 0.01 level (2-tailed). 
Note. Visual Puzzles, Matrix Reasoning, EXIT, and Crossing-Off not calculated for the non-demented participants 
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Insulin 
 Total area under the curve (AUC) for blood glucose and insulin concentration over time 
served as overall indices for glucose and insulin levels. The AUC values were calculated based 
on the 120-minute glucose tolerance test. Simple independent t tests were used to compare the 
average insulin AUC for the PD group and PDD groups. The average insulin AUC for the PD 
group (M = 4682.40) did not significantly differ from the PDD group (M = 4301.15, t = .45, p = 
.66). However, the average insulin AUC for the PD group significantly differed from the average 
insulin AUC for the ND control group (M = 3126.30, t = – 2.53, p = .016). The average insulin 
AUC for the PDD group did not differ significantly from the ND control group (M = 4301.15, t = 
1.81, p = .08). Insulin AUC values were not significantly related to age, MMSE scores, or 
UPDRS motor scores for all three groups. Correlations between insulin AUC values and 
demographic information for the three groups are shown in Table 5. 
 
Table 5 
Correlations between demographic information and insulin AUC 
______________________________________________________________________________ 
	   	   	   	   	   	  
Insulin AUC 
   _________________________________________________________________ 
 
    Non-Demented           PD Participants             PDD Participants               
       R             p          R                   p  R          p 
______________________________________________________________________________	  
 
Age                           – .141             .532        .097              .765                .200               .579  
           
MMSE                           – .079           .725     – .224              .483                .149               .681  
              
UPDRS                               --                  --     – .369              .238             – .446               .196 
_____________________________________________________________________________________	  
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
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 One-way between subjects analysis of variance (ANOVA) was used to compare the 
means of the ND control, PD, and PDD groups on insulin levels at each of the 13 time points of 
the glucose tolerance test. The mean insulin levels at each time point of the glucose tolerance test 
are shown in Table 6. The three groups differed significantly on baseline insulin levels (i.e.,  -5 
minute time point), F(2,41) = 5.25, p = .009. Bonferroni post hoc procedure was used because it 
is a conservative approach that reduces the opportunity for Type I errors. Post hoc analysis 
indicated that participants in the PD group (M = 15.83, SD = 4.13, p = .03) and the PDD group 
(M = 15.80, SD = 7.05, p = .04) had significantly higher baseline insulin levels compared to 
participants in the ND control group (M = 10.95, SD = 4.26). Baseline insulin levels did not 
significantly differ between the PD and PDD groups. Figure 1 illustrates the means for the 
baseline insulin levels for the three groups. The three groups also differed significantly on insulin 
levels at the one-minute time point, [F(2,41) = 4.73, p = .014], the 30-minute time point, 
[F(2,41) = 5.69, p = .007], the 40-minute time point, [F(2,41) = 6.62, p = .003], the 50-minute 
time point, [F(2,41) = 3.92, p = .028], the 90-minute time point, [F(2,41) = 3.75, p = .032], and 
the 120-minute time point, [F(2,41) = 3.45, p = .041]. The PD group had the highest insulin 
value at 120 minutes (M = 18.30). The three groups differed significantly on the insulin AUC 
value, F(2,41) = 3.46, p = .041. Figure 2 illustrates the insulin AUC for the three groups at the 
120-minute time point. 
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Table 6 
Mean insulin levels at each time point of glucose tolerance test 
______________________________________________________________________________ 
	   	   	   	   	   	  
   Insulin  
   _________________________________________________________________ 
 
    Non-Demented           PD Participants             PDD Participants               
       M            SD          M                  SD  M         SD 
______________________________________________________________________________	  
 
Time points 
 
- 5 minute (baseline)        10.95           4.26       15.84   4.13               15.80              7.05 
1 minute                44.59          47.37       80.17            52.79              24.30            10.32       
3 minute  109.86         83.32     143.75  89.54          105.00            45.92              
5 minute  100.23         67.18     114.33  74.73            89.80            44.81          
10 minute    53.45         37.37               59.08  36.25            63.30       25.56  
15 minute    37.18         22.83       53.17  30.41            53.70       23.23             
20 minute    31.73         18.09       47.54  25.97            46.00            22.58              
30 minute    25.91         13.38       44.00  19.74            40.70       18.49              
40 minute                         23.05          11.52       42.58            22.07              39.70            19.19            
50 minute                         23.14         13.76       38.75            18.90              34.80            19.77               
60 minute                         21.86          13.93       36.33            19.31              32.50            22.10 
90 minute                         15.14            6.97       23.83            11.87              24.20            15.47              
120 minute                       12.00            5.82       16.92              6.08              18.30            10.29                
_____________________________________________________________________________________	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Figure 1. Means for baseline insulin values for the ND, PD, and PDD groups. 
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Figure 2. Means for insulin AUC values at the 120-minute time point for the ND control, PD, 
and PDD groups. 
 
 
Using bivariate correlations, insulin AUC values for participants in the PD group were 
significantly related to performance on measures of executive functioning [i.e., Stroop Word 
subtest (r = – .65, p = .022) and EXIT (r = .65, p = .022)]. In the PDD group, performance on 
executive functioning [i.e., Category Fluency - Vegetables (r = .631, p = .050)] was also 
significantly related to insulin AUC values. In the ND control group, insulin AUC was also 
significantly correlated with measures of executive functioning [i.e., Trail Making A (r = – .53, p 
= .011) and Stroop Interference subtest (r = .55, p = .009)] and processing speed [Digit Symbol 
(r = - .50, p = .024)]. Insulin AUC values were not significantly related to measures of memory, 
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working memory, language, visuospatial ability, or simple motor speed in the three groups. 
Table 7 shows the correlations between performance on neuropsychological measures and 
insulin AUC. 
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Table 7 
Correlations between neuropsychological measure performances and insulin AUC 
______________________________________________________________________________ 
	   	   	   	   	   	  
Insulin AUC 
   _________________________________________________________________ 
 
    Non-Demented           PD Participants             PDD Participants               
       R             p          R                   p  R          p 
______________________________________________________________________________	  
 
Memory 
Logical Mem I              – .005           .981     – .243   .447             – .102              .778              
Logical Mem II                 .025             .914     – .126              .697             – .189              .601                 
SRT 
 T1-FR     .134           .552        .215   .502             .593              .071              
 T1-CR  – .134           .552     – .220   .492             .095              .794           
 T2-FR  – .003           .988             – .207   .519             .477        .164  
 T2-CR     .003           .988        .207   .519             .214        .553              
 T3-FR  – .083           .714     – .097   .764             .325              .360              
 T3-CR     .263           .238        .097   .764             .301        .398              
Working Memory 
Digit Span F                   – .181             .419     – .360              .250                .522               .122            
Digit Span B                  – .229           .305     – .458              .135             – .245               .495               
Letter-Number Seq           .159             .481     – .231              .469             – .203               .574 
Executive Functioning 
Category Flu Ani           – .182             .418        .033              .919                .291               .415               
Category Flu Veg          – .195             .385     – .567              .054                .631*             .050           
Trails A                          – .528*           .011        .182              .572             – .201               .578               
 Errors A               .519*           .013     – .017              .959                .517               .126                  
Trails B                          – .412             .056        .365              .243                .057               .875               
 Errors B            – .119             .599        .450              .143                .105               .773               
Stroop (# correct) 
 Color                 – .034             .885     – .500              .098                .179               .621              
 Word                 – .089             .660     – .649*            .022                .554               .097              
 Interference          .554**         .009     – .530              .076                .124               .734                 
EXIT-25                              --                 --        .649*            .022             – .372               .290                   
Visuospatial  
Block Design                    .260              .255        .305              .335                .176               .627                  
Visual Puzzles       --               --     – .104   .747             .260         .469                
Matrix Reasoning      --             --     – .123   .704          – .013         .972                
Language 
Boston Naming                 .202              .379        .017              .959                .456               .185                 
Processing Speed 
Digit Symbol                    .501*            .024     – .045   .089                .353               .318                  
Simple Motor Speed 
Crossing-Off                        --                 --        .241              .450                .603               .065                    
_____________________________________________________________________________________	  
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
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Linear regressions were calculated to determine if group x metabolic interactions existed 
in predicting cognitive performance on neuropsychological measures. Insulin AUC was used to 
represent metabolic values. In the PD group, insulin AUC significantly predicted performance on 
measures of executive functioning, including the word-reading subtest of the Stroop Color-Word 
test: [F(1,10) = 7.27, p = .02, R2 = .42], with higher word-reading subtests scores (i.e., less 
impairment) associated with lower insulin AUC. Insulin AUC also predicted performance on the 
EXIT: [F(1,10) = 7.28, p = .02, R2 = .42], with higher EXIT scores (i.e., greater cognitive 
impairment) associated with higher insulin AUC. In the PDD group, insulin AUC significantly 
predicted performance on only one measure of executive functioning, Category Fluency – 
Vegetables: [F(1,8) = 5.29, p = .05, R2 = .40], with lower Category Fluency – Vegetables scores 
(i.e., greater impairment) associated with higher insulin AUC. Based on regression results, 
participants in the PD and PDD groups performed better on measures of executive functioning 
when insulin AUC were lower and demonstrated greater cognitive impairments when insulin 
AUC were higher. Similar predictions of cognitive performance in the areas of memory, working 
memory, language, visuospatial functioning, processing speed, and simple motor speed based on 
insulin AUC and PD and PDD group designation were not established.  
Discussion  
Reductions in insulin hormone and insulin receptor expression and damage to 
glucoregulatory mechanisms are more common as age increases (Cardoso et al., 2009). These 
changes trigger impaired glucose tolerance, insulin resistance, and diabetes mellitus (Gasparini, 
Netzer, Greengard, & Xu, 2002; Sandyk, 1993). Inadequately regulated insulin in diabetes 
mellitus leads to poorer cognitive functioning and more rapid cognitive decline over time 
(Arvanitakis et al., 2006; Gregg et al., 2000; Messier & Teutenberg, 2005). While numerous 
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studies have illustrated the relationship between insulin and AD, there is a paucity of data on 
insulin’s association to PD and PDD. We hypothesized that (1) the PDD group would have lower 
absolute insulin compared to PD and control groups; (2) Lower insulin levels would significantly 
correlate with decreased motor performance, as defined by the Unified Parkinson’s Disease 
Rating Scale (UPDRS) motor score; (3) Lower insulin levels would predict poorer performance 
on executive functioning, memory, visuospatial, and language tasks. This study demonstrated a 
relationship between insulin and motor performance as well as a connection between insulin and 
executive functioning performance in the PD and PDD groups. 
Hypothesis 1 – absolute insulin 
 Results demonstrated that participants in the PDD group had lower absolute insulin 
values compared to the PD group when measured by the insulin area under the curve (AUC) for 
a two-hour glucose tolerance test. However, insulin AUC values did not differ significantly 
between the PD and PDD groups. This finding was consistent with previous research that 
demonstrated a connection between insulin levels and reduced cognitive functioning (Cardoso et 
al., 2009; Gasparini et al., 2002). For example, in a study using a similar protocol, lower insulin 
AUC levels were associated with higher dementia severity in individuals with AD (Burns et al., 
2007). Based on the nature of the diagnosis, PDD participants typically demonstrate increased 
dementia severity compared to individuals with only a PD diagnosis.  
In addition, the link between lower insulin levels and increased dementia severity found 
in this study adds support to the connection between lower insulin levels and reduced 
performance in various cognitive domains. An established relationship exists between lower 
insulin levels and impaired insulin signaling, a key feature of diabetes mellitus (White, 2003). 
Individuals with diabetes mellitus were found to have lower scores than non-diabetic individuals 
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on tasks of attention, psychomotor function, and executive functioning (Nandipati, Luo, 
Schimming, Grossman, & Sano, 2011). Diabetes mellitus also led to rapid decline in cognitive 
functioning (Arvanitakis et al., 2006; Cardoso et al., 2009; Gregg et al., 2000; Messier & 
Teutenberg, 2005). This study and others provide convergent evidence for higher dementia rates 
among those with both PD and diabetes mellitus (Sandyk, 1993) and highlights the need for 
additional research in the area to clarify how insulin is related to PD and PDD. 
Hypothesis 2 - motor 
 Results showed a relationship between insulin AUC and motor performance such that 
lower insulin was associated with reduced motor performance. This relationship was consistent 
with previous research that demonstrated how diabetes is connected to parkinsonian symptoms 
including postural reflexes and gait disturbances (Arvanitakis et al., 2007), and connected to 
increased motor severity (Papapetropoulos, et al., 2004). The connection between reduced motor 
performance and lower insulin is likely attributed to the neuroanatomy of PD and brain structures 
involved in the insulin signaling pathway. For example, a loss of neurons within the substantia 
nigra was accompanied by reduced insulin receptors in those with PD. In addition, animal studies 
showed that hypoinsulinemia (i.e., low insulin in blood) was associated with reduced dopamine 
transporters in the substantia nigra (Cardoso et al., 2009). These findings are consistent with the 
current study and help explain why participants showed poorer UPDRS motor performance when 
insulin levels were lower.  
We established a relationship between insulin and motor performance; however, the 
relationship was clinically notable rather than statistically significant. One possible explanation 
for why only clinically notable results were found between insulin and motor performance is all 
participants were asked to take their usual PD medications before completing the UPDRS and 
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other screening measures. The medications, most commonly levodopa or carbidopa-levodopa, 
likely blunted the true impact of motor dysfunction that patients experience when not taking 
medications. Despite not reaching the level of statistical significance, this information is useful 
for individuals with PD, particularly if comorbid with diabetes mellitus. Obtaining appropriate 
treatments to relieve motor symptoms may become more challenging with both diseases, as 
participants in this study still demonstrated reduced motor performance despite being on 
medications aimed at controlling physical symptoms of PD. Furthermore, these findings could 
assist doctors in recommending exercises targeted for increased motor flexibility and safety if 
PD patients are diagnosed with diabetes mellitus.  
Hypothesis 3 – neuropsychology performance 
 Results did not demonstrate that lower insulin levels predicted poorer performance on 
executive functioning, memory, visuospatial, and language tasks. Instead, we found that higher 
insulin levels predicted poorer performance only in the area of executive functioning for both the 
PD and PDD groups. This inverse relationship was opposite to what was expected in this 
population given previous evidence that associated lower insulin levels with reduced cognitive 
performance (Cardoso et al., 2009; Gasparini et al., 2002). Past studies found that administering 
optimal doses of nasal and intravenous insulin actually increased cognitive performance, 
particularly in the area of verbal and declarative memory (Benedict et al., 2007; Bourdel-
Marchasson, Lapre, Laksir, & Puget, 2010; Reger et al., 2006). In addition, the finding that 
higher insulin AUC levels predicted poorer cognitive performance is opposite to what 
researchers found in individuals with AD. Increased insulin levels were associated with greater 
cognitive performance in AD (Bourdel-Marchasson et al., 2010; Burns et al., 2007). Results from 
the current study are surprising given the similarities among AD, PD, and PDD. 
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One possible explanation for the relationship between higher insulin levels and poorer 
executive functioning performance could be that tests measuring executive functioning activate 
specific pathways and structures within the brain, many of which are also connected to insulin 
and insulin signaling. Brain structures involved in executive functioning include the cerebral 
cortex, hippocampus, and hypothalamus. Tests activating the cerebral cortex, specifically the 
prefrontal cortex, use the frontostriatal system. Executive functioning tests that use this system 
require gradual learning through trial and error and is demonstrated through skill learning, 
planning, set shifting, and habit formation. Alternatively, some executive functioning tests use 
the hippocampal system that requires a rapid and flexible system of learning (Leh, Petrides, & 
Strafella, 2010). As individuals compete tasks of executive functioning, the frontostriatal and 
hippocampal systems may act independently, work together, or compete with each other 
depending on the demands of the specific test.  
The two main brain systems participating in executive functioning abilities involve the 
cerebral cortex and the hippocampus, both of which are key structures concerning insulin in the 
brain. These two structures along with the hypothalamus are among the structures with the 
highest concentrations of insulin receptors (Leh et al., 2010; Weintraub et al., 2011). Because 
these particular structures have a high concentration of insulin receptors, the effects of increasing 
age and reduced insulin hormone are noticeable. In addition, chronic hyperinsulinemia (i.e., 
excessive insulin in blood) both increases genes responsible for inflammatory and immune 
pathways and decreases genes responsible for insulin signaling. These changing gene levels 
result in blocked glucose usage and reduced mitochondrial functioning in hippocampal neurons 
(Blalock et al., 2010). This reduced functioning is demonstrated through diminished activity of 
several mitochondrial enzymes (e.g. pyruvate and isocitrate dehydrogenases, a-ketoglutarate 
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dehydrogenase complex) that are components of the citric acid cycle and energy production. 
Researchers have found evidence for this reduced mitochondrial functioning and mitochondrial 
enzymes in brain tissue samples from patients with AD (Bubber et al., 2005, as cited in Aviles-
Olmos, Limousin, Lees, & Foltynie, 2012). Because of similarities between AD and PD, it is 
possible that reduced mitochondrial functioning associated with hyperinsulinemia may explain 
why higher insulin levels were connected to poorer executive functioning performance. Due to 
the hippocampus’ connections to both insulin and executive functioning, it is important to 
investigate this area further so see if generalizations can be applied to individuals with PD and 
PDD or if results from this study are unique to our sample.  
While this study demonstrated connections between insulin and executive functioning, 
results did not support previous research that showed relationships between insulin and reduced 
performance on tasks of memory. In a study using magnetic resonance imaging (MRI), reduced 
hippocampal and prefrontal cortex volumes were associated with declarative memory in 
individuals with diabetes. Also, individuals with diabetes demonstrated greater difficulties in 
tasks of short-term memory compared to those without diabetes (Bourdel-Marchasson et al., 
2010). Despite the hippocampus’ involvement in both memory and insulin, it is possible that 
higher concentrations of insulin receptors exist in the hippocampus compared to the cerebral 
cortex and hypothalamus. Therefore, reductions in insulin receptors and insulin levels may result 
in less damage to memory performance and more damage to the cerebral cortex and 
hypothalamus involved in executive functioning. This could explain why executive dysfunctions 
are common and among the first to be seen in both PD and PDD.  
Overall, even though this study supported previous research by showing a connection 
between insulin levels and executive functioning in PD and PDD, the exact mechanism to 
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explain the relationship is unknown. Furthermore, it is unknown why higher insulin levels 
predicted poorer cognitive performance on executive functioning measures, particularly when 
past research demonstrated a relationship between reduced cognitive performance, especially 
memory performance, and lower insulin levels. Additional research to replicate this finding and 
better clarify potential mechanisms for the relationship is warranted.    
Limitations 
 This study was limited by the unique participant sample. The exclusion criteria (i.e., ages 
55-85, diagnosis of PD, no diagnosis of Type I or Type II diabetes mellitus or Alzheimer’s 
disease) produced a small sample size for all three participant groups. Each group had fewer than 
25 participants, with the PD and PDD groups having less than 13 participants, which may have 
impacted the power available to accurately draw conclusions based on results. A small sample 
size opens the possibility that results are due to chance (Type I error) and not actual differences 
between high or low insulin levels and neuropsychological performance in PD and PDD. Also, 
the criteria of no diagnosis of diabetes mellitus severely limited the sample of older adult 
participants given that prevalence rates of diabetes are increasing among the older adult 
population (Arvanitakis et al., 2006). In addition, there was little diversity in the participant 
sample. The participant sample consisted of only Caucasians, the majority of participants within 
the PDD group were men (90%), and all participants were in the mild to moderate stages of PD. 
These factors limited the ability to generalize findings to all older adults with PD or PDD.  
 While care was taken to develop a neuropsychological battery that was a comprehensive 
evaluation comprised of commonly used tests lasting approximately 1.5 hours, the length of 
testing may have been too long for some participants. Behavioral observations included fatigue 
near the end of the testing process, particularly within the PDD group. Fatigue may have 
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negatively skewed performance on the neuropsychological measures. Also, two of the three 
measures used to evaluate visuospatial ability were near the end of the neuropsychological 
battery. It is possible that performances on these measures were not accurate and could account 
for the lack of significant findings with respect to performance and insulin levels. Due to the 
high frequency with which visuospatial deficits are reported in PD and PDD (Robottom & 
Weiner, 2009; Stepkina et al., 2010), it was thought that significant correlations between insulin 
and visuospatial ability would have presented. 
 Furthermore, peripheral insulin levels from blood were used rather than insulin from 
within the central nervous system. High insulin levels correlate with the concentration of insulin 
receptors, with the highest concentration of insulin receptors found in the cerebral cortex, 
hippocampus, hypothalamus, olfactory bulb, and cerebellum (Cardoso et al., 2009; Rahman, 
2011). Therefore, insulin gathered from blood rather than the central nervous system may have 
limited the accuracy of insulin levels. Due to the design of this study, collecting insulin levels 
from the central nervous system was not feasible and research using insulin levels from these 
sources is limited (Rahman, 2011). Future research using insulin from the cerebral spinal fluid 
may provide greater accuracy of insulin levels at different time points and may help to clarify the 
connection between insulin and performance on measures of executive functioning.  
Future directions and conclusions 
 Future work should strive to include larger sample sizes and greater diversity that would 
more effectively represent older adults with PD and PDD. Including more women with PDD and 
individuals of minority status would allow results to be more effectively generalized to the 
broader population of those with the disease. In addition, using samples that include mild, 
moderate, and advanced stages of PDD would highlight whether executive functioning 
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performance continues to have significant associations to insulin levels or if different cognitive 
domains (e.g., memory, visuospatial ability, language, processing speed) are more strongly 
impacted as the disease progresses. Including participants with mild cognitive impairment (MCI) 
would also explore a category of PD patients that is under researched and highlight potential 
distinctions from those with normal cognition and those with PDD (Weintraub et al., 2011). 
Future studies should also use different neuropsychological measures to evaluate various 
aspects of cognitive performance. Alternative measures evaluating memory, visuospatial ability, 
language, among other domains, may shed greater light on the connection between overall 
cognitive performance and insulin. Measures of executive functioning including the Delis-
Kaplan Executive Function System (D-KEFS), Wisconsin Card Sorting Task, Tower of London 
(Leh et al., 2010), and Dementia Rating Scale-2 (Weintraub et al., 2011) are possible 
neuropsychological measures that could help determine if the significant connections between 
executive functioning and insulin are consistent across measures. Also, care should be taken to 
gather a comprehensive evaluation without over-taxing participants that may negatively skew 
results.  
In addition, greater investigation into the connection between motor performance and 
insulin should be explored. Finally, due to the cross sectional nature of the data, causal 
conclusions cannot be formed. It is possible that a third process is acting on the population and 
may be revealed as the disease progresses. Longitudinal studies would be appropriate to see if 
higher insulin levels continue to predict poorer performance on measures of executive 
functioning in PD and PDD.   
 Despite limitations to the current study, the results expand literature, especially the 
relative lack of research examining the connection between insulin levels and cognitive 
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performance in those with PD or PDD. This study demonstrated a connection between insulin 
levels and executive functioning. However, more research is needed to establish the specific 
mechanisms for this connection and provide further evidence for insulin’s role in cognitive 
changes for older adults with PD, PDD, and other neurodegenerative diseases.  
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